GHK-Cu is one of the more extensively documented peptides in this atlas, with claims tied to modulation of a large fraction of the human genome relevant to tissue remodeling. It's studied for upregulating collagen, elastin, and antioxidant-defense pathways, and for anti-inflammatory activity via NF-κB and p38 MAPK inhibition — the mechanistic basis for its long history in cosmetic dermatology as well as newer wound-healing and hair-follicle research.

‍

• Cosmetic skincare: widely available over the counter in topical anti-aging serums, unlike almost everything else in this collection
• Compounding-clinic injectable protocols for skin, hair, and wound-healing applications
• Base component of combination blends elsewhere in this atlas (Glow, Klow)

• The only peptide in this atlas with a genuinely mainstream, over-the-counter cosmetic identity alongside its injectable/research-chemical form — two very different regulatory worlds for the same molecule
• As of May 2026, non-injectable GHK-Cu sits in FDA Category 1 (legally compoundable) after a nominator clarified its withdrawal applied only to the injectable route; injectable GHK-Cu remains among the peptides removed from Category 2 in April 2026, with formal review not expected until before February 2027
• Decades of topical-cosmetic use give it a longer real-world human safety record than most peptides here, though that record doesn't extend to injectable or high-dose systemic use